bioRxivImmunologyPreprint
New strategy to select cross-reactivity Meningococci strains: immunization with Outer membrane vesicles of serogroup C and cationic lipid as adjuvant
Abstract
BackgroundInvasive meningococcal disease (IMD), caused by Neisseria meningitidis, is a public health problem, associated with high levels of morbidity and mortality, capable of causing outbreaks or epidemics, but preventable through vaccination. In Brazil, the main serogroups isolated are C and B. The last epidemic occurred in the 80s, in Sao Paulo, because of a B:4:P1.15 strain. MethodsAdult Swiss mice were immunized with outer membrane vesicles (OMV) of N. meningitidis strain C:4:P1.15, adjuvanted by the cationic lipid dioctadecyldimethylammonium bromide in bilayer fragments (DDA-BF), administered via prime-booster (intranasal/subcutaneous) scheme. The humoral response was accessed by Immunoblotting and ELISA, using homologous immunization strain and a different serogroup but equal serosubtype strain, N. meningitidis B:4:P1.15. ResultsImmunoblotting revealed the recognition of antigens associated with the molecular weight of Porin A and Opacity proteins, which are immunogenic but highly heterogeneous, and Tbp and NspA, which are more homogeneous between meningococci strains. ELISA results showed antibody production that persisted after 190 days and recognized the C:4:P1.15 and the B:4:P1.15 strains, with high avidity index. The adjuvanted group recognized antigens following the IN prime and had a higher avidity index against the heterologous strain. ConclusionsDDA-BF improved the humoral response, but the OMV alone induced high avidity index antibodies as well. Even though these are preliminary results, we see it as a promising approach for affordable meningococcal immunization in developing countries, at outbreak or epidemic situations.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Production and control of a Brazilian tailor-made meningococcal B vaccineShort title: Brazilian meningococcal B vaccine production
E. Jessouroun, A. P. Santos, … M. d. L. M. Leal·bioRxiv·Aug 13, 2021
- Protection against N. gonorrhoeae induced by OMV-based Meningococcal Vaccines are associated with cross-species directed humoral and cellular immune responses
Weiyan Zhu, Andreea Waltmann, … Joseph A. Duncan·Frontiers in ImmunologyPeer-reviewed·Apr 11, 2025
- The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae
I. Leduc, K. L. Connolly, … A. Jerse·PLOS PathogensPeer-reviewed·Dec 8, 2020
- Structural dynamics and immunogenicity of the recombinant and outer membrane vesicle-embedded Meningococcal antigen NadA
V. Calvaresi, L. Dello Iacono, … N. Norais·bioRxiv·Jan 30, 2024
- Preclinical characterization of immune responses induced by a candidate gonococcal native Outer Membrane Vesicle vaccine
Ilaria Onofrio, Sthefany Pagliari, … Calman Alexander MacLennan·mSpherePeer-reviewed·Jun 22, 2026
- Rationally designed minimized TbpB confers broad protection against meningococcal infection
Epshita A. Islam, Jamie E. Fegan, … Scott D. Gray‐Owen·PLoS PathogensPeer-reviewed·Aug 10, 2026